 Timothy Jenkins
Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 46 | 2026 | 1923 | 7.290 |
Why?
| | Antimicrobial Stewardship | 13 | 2025 | 130 | 4.610 |
Why?
| | Otitis Media | 9 | 2026 | 182 | 4.210 |
Why?
| | Bacteremia | 10 | 2025 | 222 | 3.210 |
Why?
| | Skin Diseases, Bacterial | 7 | 2016 | 22 | 2.560 |
Why?
| | Staphylococcal Infections | 7 | 2025 | 391 | 2.270 |
Why?
| | Practice Patterns, Physicians' | 12 | 2026 | 1371 | 1.870 |
Why?
| | Drug Utilization | 5 | 2020 | 168 | 1.790 |
Why?
| | Inappropriate Prescribing | 6 | 2021 | 66 | 1.760 |
Why?
| | Soft Tissue Infections | 4 | 2018 | 40 | 1.660 |
Why?
| | Cross Infection | 3 | 2025 | 260 | 1.350 |
Why?
| | Staphylococcus aureus | 5 | 2025 | 451 | 1.260 |
Why?
| | Abscess | 4 | 2015 | 77 | 1.260 |
Why?
| | Drug Prescriptions | 4 | 2026 | 288 | 1.230 |
Why?
| | Anti-Infective Agents | 7 | 2020 | 232 | 1.210 |
Why?
| | Spermatozoa | 3 | 2026 | 106 | 1.170 |
Why?
| | Conjunctivitis | 4 | 2024 | 30 | 1.140 |
Why?
| | Ambulatory Care | 6 | 2020 | 609 | 1.100 |
Why?
| | Skin Diseases | 3 | 2015 | 152 | 1.060 |
Why?
| | Otitis | 2 | 2024 | 9 | 1.020 |
Why?
| | DNA Methylation | 4 | 2026 | 674 | 1.010 |
Why?
| | Respiratory Tract Infections | 2 | 2026 | 396 | 0.980 |
Why?
| | Multiplex Polymerase Chain Reaction | 2 | 2026 | 56 | 0.970 |
Why?
| | Hospitalization | 7 | 2017 | 2460 | 0.950 |
Why?
| | Patient Harm | 1 | 2025 | 4 | 0.930 |
Why?
| | Acute Disease | 9 | 2026 | 1036 | 0.910 |
Why?
| | Retrospective Studies | 31 | 2026 | 17291 | 0.880 |
Why?
| | Watchful Waiting | 1 | 2025 | 90 | 0.880 |
Why?
| | Endocarditis, Bacterial | 1 | 2025 | 46 | 0.840 |
Why?
| | Urinary Tract Infections | 4 | 2025 | 210 | 0.840 |
Why?
| | Catheterization, Peripheral | 1 | 2025 | 120 | 0.830 |
Why?
| | Amoxicillin | 1 | 2024 | 35 | 0.800 |
Why?
| | Guideline Adherence | 4 | 2022 | 586 | 0.760 |
Why?
| | Humans | 74 | 2026 | 145474 | 0.750 |
Why?
| | Cellulitis | 2 | 2014 | 54 | 0.750 |
Why?
| | Clinical Decision-Making | 1 | 2025 | 363 | 0.710 |
Why?
| | Fluoroquinolones | 3 | 2024 | 44 | 0.680 |
Why?
| | Hospitalists | 1 | 2025 | 267 | 0.670 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 639 | 0.670 |
Why?
| | Conjunctivitis, Bacterial | 3 | 2024 | 12 | 0.630 |
Why?
| | Gram-Negative Bacterial Infections | 2 | 2018 | 49 | 0.630 |
Why?
| | Inpatients | 3 | 2020 | 553 | 0.630 |
Why?
| | Child | 21 | 2026 | 22707 | 0.610 |
Why?
| | Computational Biology | 1 | 2024 | 669 | 0.590 |
Why?
| | Drug Resistance, Bacterial | 3 | 2017 | 185 | 0.550 |
Why?
| | Pharyngitis | 1 | 2018 | 25 | 0.540 |
Why?
| | Substance Abuse, Intravenous | 2 | 2020 | 127 | 0.540 |
Why?
| | Clinical Competence | 1 | 2025 | 1243 | 0.510 |
Why?
| | Smartphone | 1 | 2018 | 106 | 0.510 |
Why?
| | Nitrofurantoin | 1 | 2017 | 9 | 0.500 |
Why?
| | Infection Control | 2 | 2017 | 173 | 0.500 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2017 | 16 | 0.500 |
Why?
| | Cystitis | 1 | 2017 | 24 | 0.500 |
Why?
| | Colorado | 9 | 2020 | 4553 | 0.490 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1419 | 0.490 |
Why?
| | Male | 36 | 2026 | 72842 | 0.480 |
Why?
| | Infertility, Male | 2 | 2026 | 80 | 0.470 |
Why?
| | Administration, Intravenous | 3 | 2025 | 172 | 0.460 |
Why?
| | Emergency Service, Hospital | 6 | 2025 | 2381 | 0.460 |
Why?
| | Sinusitis | 1 | 2018 | 227 | 0.450 |
Why?
| | Mobile Applications | 1 | 2018 | 199 | 0.450 |
Why?
| | Epigenesis, Genetic | 3 | 2026 | 679 | 0.440 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 29 | 0.440 |
Why?
| | Semen Analysis | 3 | 2026 | 15 | 0.440 |
Why?
| | Drug Users | 1 | 2015 | 43 | 0.440 |
Why?
| | Female | 36 | 2026 | 78844 | 0.440 |
Why?
| | Child, Preschool | 12 | 2026 | 11853 | 0.430 |
Why?
| | Medication Therapy Management | 1 | 2015 | 72 | 0.410 |
Why?
| | Adult | 28 | 2026 | 40777 | 0.410 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 43 | 0.410 |
Why?
| | Treatment Outcome | 10 | 2025 | 11772 | 0.410 |
Why?
| | Infant | 10 | 2026 | 10077 | 0.400 |
Why?
| | Arthritis, Infectious | 2 | 2024 | 76 | 0.380 |
Why?
| | Middle Aged | 21 | 2025 | 36215 | 0.380 |
Why?
| | Practice Guidelines as Topic | 4 | 2017 | 1581 | 0.380 |
Why?
| | Cohort Studies | 9 | 2024 | 6013 | 0.370 |
Why?
| | Osteomyelitis | 2 | 2012 | 145 | 0.370 |
Why?
| | Escherichia coli | 1 | 2017 | 835 | 0.370 |
Why?
| | Administration, Oral | 2 | 2025 | 866 | 0.360 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2023 | 251 | 0.360 |
Why?
| | Streptococcus pneumoniae | 2 | 2023 | 184 | 0.360 |
Why?
| | Community-Acquired Infections | 5 | 2017 | 177 | 0.360 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2012 | 47 | 0.350 |
Why?
| | Patient Discharge | 2 | 2017 | 992 | 0.350 |
Why?
| | Critical Pathways | 1 | 2013 | 109 | 0.350 |
Why?
| | Aged, 80 and over | 8 | 2025 | 8333 | 0.340 |
Why?
| | Histoplasmosis | 1 | 2011 | 15 | 0.340 |
Why?
| | Drug Utilization Review | 3 | 2016 | 61 | 0.340 |
Why?
| | Humeral Head | 1 | 2011 | 21 | 0.340 |
Why?
| | Fistula | 1 | 2011 | 49 | 0.330 |
Why?
| | Muscular Diseases | 1 | 2011 | 108 | 0.320 |
Why?
| | Arm | 1 | 2011 | 110 | 0.320 |
Why?
| | Urinalysis | 2 | 2025 | 83 | 0.320 |
Why?
| | Logistic Models | 3 | 2024 | 2134 | 0.310 |
Why?
| | Debridement | 3 | 2024 | 85 | 0.310 |
Why?
| | Ambulatory Care Facilities | 2 | 2024 | 269 | 0.300 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2025 | 1747 | 0.290 |
Why?
| | Academic Medical Centers | 4 | 2024 | 554 | 0.280 |
Why?
| | Aged | 12 | 2025 | 26153 | 0.280 |
Why?
| | Outpatients | 3 | 2021 | 447 | 0.280 |
Why?
| | Sperm Count | 2 | 2026 | 22 | 0.270 |
Why?
| | Sepsis | 2 | 2024 | 664 | 0.250 |
Why?
| | Haemophilus influenzae | 2 | 2024 | 67 | 0.250 |
Why?
| | Hospitals | 3 | 2024 | 732 | 0.250 |
Why?
| | Prescriptions | 2 | 2018 | 74 | 0.240 |
Why?
| | Drug and Narcotic Control | 2 | 2016 | 24 | 0.240 |
Why?
| | Pyuria | 1 | 2025 | 5 | 0.230 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 1097 | 0.230 |
Why?
| | Health Services Research | 1 | 2008 | 391 | 0.230 |
Why?
| | Semen | 2 | 2026 | 24 | 0.220 |
Why?
| | Unnecessary Procedures | 1 | 2025 | 54 | 0.220 |
Why?
| | Decision Support Techniques | 2 | 2024 | 477 | 0.220 |
Why?
| | C-Reactive Protein | 2 | 2024 | 422 | 0.220 |
Why?
| | Penicillins | 1 | 2025 | 62 | 0.220 |
Why?
| | HIV | 1 | 2006 | 251 | 0.210 |
Why?
| | Mycoses | 1 | 2025 | 88 | 0.210 |
Why?
| | Crystal Arthropathies | 1 | 2024 | 2 | 0.210 |
Why?
| | Drug Administration Schedule | 3 | 2024 | 782 | 0.210 |
Why?
| | Fungi | 1 | 2025 | 121 | 0.210 |
Why?
| | Child Care | 1 | 2024 | 36 | 0.210 |
Why?
| | Mycobacterium | 1 | 2025 | 101 | 0.210 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.210 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2018 | 303 | 0.200 |
Why?
| | Absenteeism | 1 | 2024 | 52 | 0.200 |
Why?
| | Therapeutic Irrigation | 1 | 2024 | 68 | 0.200 |
Why?
| | beta-Lactamases | 1 | 2024 | 53 | 0.200 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 134 | 0.200 |
Why?
| | Drug Hypersensitivity | 1 | 2025 | 90 | 0.200 |
Why?
| | Daptomycin | 1 | 2023 | 18 | 0.200 |
Why?
| | Nursing Staff, Hospital | 1 | 2025 | 143 | 0.200 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2024 | 133 | 0.190 |
Why?
| | Program Evaluation | 3 | 2017 | 943 | 0.190 |
Why?
| | United States | 5 | 2025 | 16098 | 0.190 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2025 | 194 | 0.190 |
Why?
| | Pandemics | 2 | 2022 | 1707 | 0.190 |
Why?
| | Adolescent | 8 | 2026 | 22529 | 0.190 |
Why?
| | Organizational Policy | 2 | 2017 | 78 | 0.190 |
Why?
| | Orthopedic Procedures | 1 | 2025 | 244 | 0.180 |
Why?
| | Prospective Studies | 4 | 2026 | 8057 | 0.180 |
Why?
| | Streptococcal Infections | 1 | 2025 | 171 | 0.180 |
Why?
| | Dietary Supplements | 1 | 2026 | 583 | 0.180 |
Why?
| | Hazardous Substances | 1 | 2021 | 16 | 0.180 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 20 | 0.170 |
Why?
| | Cephalosporins | 2 | 2023 | 45 | 0.170 |
Why?
| | Fertility | 2 | 2026 | 173 | 0.170 |
Why?
| | Electronic Health Records | 3 | 2024 | 1196 | 0.170 |
Why?
| | Lipids | 1 | 2026 | 707 | 0.170 |
Why?
| | Risk Factors | 6 | 2017 | 10885 | 0.170 |
Why?
| | Schools | 1 | 2024 | 448 | 0.170 |
Why?
| | Insemination, Artificial | 1 | 2020 | 12 | 0.170 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2024 | 187 | 0.170 |
Why?
| | Bacterial Infections | 2 | 2020 | 246 | 0.160 |
Why?
| | Firefighters | 1 | 2021 | 47 | 0.160 |
Why?
| | Muscle, Skeletal | 1 | 2011 | 1789 | 0.160 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2025 | 440 | 0.160 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6066 | 0.160 |
Why?
| | Private Sector | 1 | 2020 | 50 | 0.150 |
Why?
| | Drug Combinations | 2 | 2024 | 396 | 0.140 |
Why?
| | Machine Learning | 1 | 2024 | 587 | 0.140 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 64 | 0.140 |
Why?
| | Hospitals, Teaching | 1 | 2018 | 120 | 0.130 |
Why?
| | Occupational Exposure | 1 | 2021 | 355 | 0.130 |
Why?
| | Pneumonia, Bacterial | 2 | 2017 | 113 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2006 | 1101 | 0.130 |
Why?
| | Mass Screening | 1 | 2006 | 1360 | 0.130 |
Why?
| | Insurance, Health | 1 | 2020 | 310 | 0.130 |
Why?
| | Infertility | 1 | 2017 | 61 | 0.120 |
Why?
| | Medical Audit | 1 | 2017 | 77 | 0.120 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 5904 | 0.120 |
Why?
| | Drug Costs | 1 | 2017 | 117 | 0.120 |
Why?
| | Medical Records | 1 | 2017 | 192 | 0.120 |
Why?
| | Linear Models | 1 | 2018 | 845 | 0.120 |
Why?
| | Drug Resistance, Microbial | 1 | 2015 | 64 | 0.110 |
Why?
| | Time | 1 | 2015 | 84 | 0.110 |
Why?
| | Treatment Failure | 1 | 2016 | 360 | 0.110 |
Why?
| | Young Adult | 5 | 2025 | 14218 | 0.110 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.100 |
Why?
| | Synovial Fluid | 2 | 2024 | 67 | 0.100 |
Why?
| | Decision Support Systems, Clinical | 1 | 2018 | 272 | 0.100 |
Why?
| | Sperm Motility | 2 | 2026 | 37 | 0.100 |
Why?
| | Pharmacists | 1 | 2017 | 258 | 0.100 |
Why?
| | Safety Management | 1 | 2015 | 125 | 0.100 |
Why?
| | Population Surveillance | 1 | 2017 | 484 | 0.100 |
Why?
| | Diagnosis, Differential | 2 | 2024 | 1508 | 0.100 |
Why?
| | Wound Infection | 1 | 2014 | 60 | 0.100 |
Why?
| | Leukocyte Count | 2 | 2024 | 316 | 0.100 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2017 | 364 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1295 | 0.090 |
Why?
| | Age Factors | 1 | 2020 | 3342 | 0.090 |
Why?
| | Diabetic Foot | 1 | 2012 | 25 | 0.090 |
Why?
| | Catheter-Related Infections | 1 | 2013 | 96 | 0.090 |
Why?
| | Limb Salvage | 1 | 2012 | 73 | 0.090 |
Why?
| | Incidence | 2 | 2017 | 2923 | 0.090 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2012 | 80 | 0.090 |
Why?
| | Bacteria | 2 | 2023 | 765 | 0.090 |
Why?
| | Hospitals, Urban | 1 | 2012 | 142 | 0.090 |
Why?
| | Histoplasma | 1 | 2011 | 11 | 0.090 |
Why?
| | Penicillin G | 1 | 2011 | 7 | 0.080 |
Why?
| | Streptomycin | 1 | 2011 | 18 | 0.080 |
Why?
| | Databases, Factual | 1 | 2017 | 1490 | 0.080 |
Why?
| | Enterococcus faecalis | 1 | 2011 | 29 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1845 | 0.080 |
Why?
| | HIV Infections | 1 | 2006 | 3193 | 0.080 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2011 | 71 | 0.080 |
Why?
| | Blood | 1 | 2010 | 107 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2026 | 2062 | 0.080 |
Why?
| | Salmonella enteritidis | 1 | 2009 | 16 | 0.080 |
Why?
| | Salmonella Food Poisoning | 1 | 2009 | 10 | 0.080 |
Why?
| | Food Handling | 1 | 2009 | 33 | 0.080 |
Why?
| | Salmonella Infections | 1 | 2009 | 57 | 0.070 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 73 | 0.070 |
Why?
| | Fever | 2 | 2024 | 319 | 0.070 |
Why?
| | Occupational Diseases | 1 | 2009 | 165 | 0.070 |
Why?
| | Endocarditis | 1 | 2008 | 40 | 0.070 |
Why?
| | DNA, Bacterial | 1 | 2009 | 320 | 0.070 |
Why?
| | Recurrence | 1 | 2010 | 1138 | 0.060 |
Why?
| | Ultrasonography | 1 | 2011 | 785 | 0.060 |
Why?
| | Critical Care | 1 | 2013 | 702 | 0.060 |
Why?
| | DNA Fragmentation | 1 | 2026 | 40 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2011 | 466 | 0.060 |
Why?
| | Infectious Disease Medicine | 2 | 2016 | 12 | 0.060 |
Why?
| | Epidemiology | 2 | 2016 | 32 | 0.060 |
Why?
| | Radiography | 1 | 2008 | 852 | 0.060 |
Why?
| | Ohio | 1 | 2025 | 146 | 0.060 |
Why?
| | Echocardiography | 1 | 2008 | 647 | 0.050 |
Why?
| | Folic Acid | 1 | 2026 | 198 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 1997 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2013 | 961 | 0.050 |
Why?
| | Haemophilus Infections | 1 | 2024 | 45 | 0.050 |
Why?
| | Ceftazidime | 1 | 2024 | 7 | 0.050 |
Why?
| | Carbapenems | 1 | 2024 | 27 | 0.050 |
Why?
| | Aztreonam | 1 | 2023 | 11 | 0.050 |
Why?
| | Streptococcus agalactiae | 1 | 2025 | 110 | 0.050 |
Why?
| | Interrupted Time Series Analysis | 1 | 2023 | 75 | 0.050 |
Why?
| | Zinc | 1 | 2026 | 306 | 0.050 |
Why?
| | Nasopharynx | 1 | 2023 | 72 | 0.050 |
Why?
| | Family Characteristics | 1 | 2024 | 195 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2024 | 364 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2022 | 90 | 0.050 |
Why?
| | Mammals | 1 | 2024 | 286 | 0.040 |
Why?
| | ROC Curve | 1 | 2024 | 617 | 0.040 |
Why?
| | Health Impact Assessment | 1 | 2021 | 7 | 0.040 |
Why?
| | Blood Cells | 1 | 2021 | 38 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2008 | 867 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 83 | 0.040 |
Why?
| | Centrifugation, Density Gradient | 1 | 2020 | 36 | 0.040 |
Why?
| | Reoperation | 1 | 2024 | 633 | 0.040 |
Why?
| | Focus Groups | 1 | 2023 | 569 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 344 | 0.040 |
Why?
| | Health Facilities | 1 | 2020 | 85 | 0.040 |
Why?
| | Coagulase | 1 | 2018 | 6 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 79 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3904 | 0.030 |
Why?
| | Staphylococcus | 1 | 2018 | 74 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2018 | 330 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2018 | 318 | 0.030 |
Why?
| | Clinical Studies as Topic | 1 | 2017 | 12 | 0.030 |
Why?
| | Cost Savings | 1 | 2017 | 86 | 0.030 |
Why?
| | Utah | 1 | 2017 | 79 | 0.030 |
Why?
| | Health Promotion | 1 | 2024 | 775 | 0.030 |
Why?
| | DNA | 1 | 2024 | 1435 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3623 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 66 | 0.030 |
Why?
| | Pharmacy Service, Hospital | 1 | 2017 | 89 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2020 | 547 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3413 | 0.030 |
Why?
| | Research Personnel | 1 | 2017 | 184 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 558 | 0.030 |
Why?
| | Leadership | 1 | 2017 | 401 | 0.020 |
Why?
| | Pregnancy | 1 | 2025 | 7202 | 0.020 |
Why?
| | Risk Assessment | 1 | 2021 | 3747 | 0.020 |
Why?
| | Quality of Life | 1 | 2024 | 3204 | 0.020 |
Why?
| | Drug Synergism | 1 | 2011 | 354 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4295 | 0.020 |
Why?
| | Contact Tracing | 1 | 2009 | 26 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 428 | 0.020 |
Why?
| | Restaurants | 1 | 2009 | 22 | 0.020 |
Why?
| | Food Contamination | 1 | 2009 | 33 | 0.020 |
Why?
| | Minnesota | 1 | 2009 | 168 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2012 | 1266 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 4316 | 0.020 |
Why?
| | Feces | 1 | 2009 | 495 | 0.010 |
Why?
| | Disease Outbreaks | 1 | 2009 | 419 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2017 | 6447 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2012 | 5423 | 0.010 |
Why?
| | Animals | 1 | 2024 | 38030 | 0.010 |
Why?
|
|
Jenkins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|